Health & Education
European Commission authorises Daraxonrasib for pretreated metastatic pancreatic cancer
The European Commission has granted Daraxonrasib a centralised EU marketing authorisation for adults with metastatic pancreatic cancer who have had prior treatment. National agencies now negotiate reimbursement, and the drug does not cure the disease.
AI text based on reports by vrtnws.be, Mediafax.ro, ANSA.it and other publishers. Published . How it is made
For membersThe first 30 seconds for everyone. Synthetic voice (AI).
In brief
The Commission authorisation covers adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic treatment, following EMA's positive opinion in October 2026. It also applies in Iceland, Norway and Liechtenstein.
The phase 3 RASolute 302 trial enrolled 500 patients. Median overall survival is given as 13.2 months against 6.6 months in one version and 12.4 against 6.7 months in another, both versus chemotherapy.
Each national authority must receive a dossier and agree a price. Average timelines cited for Italy exceed 430 days, against just under 160 days in Germany.
The EMA opinion came in just over 100 days under an accelerated procedure, nearly half the 210-day legal timeframe.
- Summer 2026United States approves daraxonrasib
- October 2026EMA issues positive scientific opinion
- 17 NovEuropean Commission grants EU marketing authorisation
Commission approval
The European Commission has granted Daraxonrasib a centralised EU marketing authorisation for second-line treatment of metastatic pancreatic adenocarcinoma, covering adults who have already received at least one systemic treatment. The decision follows a positive opinion from the European Medicines Agency (EMA) in October 2026 and allows the tablet to be marketed in the EU, Iceland, Norway and Liechtenstein. Revolution Medicines, the US start-up that developed the drug, is its manufacturer. Chief executive and chair Mark Goldsmith said in a statement that the company is working with health systems and other stakeholders across the region to secure timely access for eligible patients, and that it is in talks with regulators worldwide to extend availability. The United States had already approved the drug earlier in summer 2026.
Trial results
The approval rests on the phase 3 RASolute 302 trial, which enrolled 500 patients with previously treated metastatic pancreatic adenocarcinoma and compared daraxonrasib with chemotherapy. The results were presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting and published in the New England Journal of Medicine. Figures in the coverage differ on median overall survival: one version gives 13.2 months against 6.6 months with chemotherapy, while another, attributed to EMA data, gives 12.4 months against 6.7 months. EMA data also reported a median progression-free survival of 7.2 months against 3.6 months with chemotherapy. At six months, estimated survival was 77.7% with daraxonrasib against 54.9% with chemotherapy, and experts cited in the reporting say the drug is an important option for a disease with a poor prognosis but does not cure it.
- Daraxonrasib
- 77.7 %
- Chemotherapy
- 54.9 %
Data from the article text
Reimbursement hurdle in Italy
Approval does not make the drug automatically available. The company must now submit a dossier to each national authority and negotiate a price. Average timelines cited for Italy exceed 430 days before the drug is also added to regional formularies, against just under 160 days in Germany. Some Italian Regions have announced purchases of the drug for individual patients, reopening debate over timely and equitable access. Under the US Most Favored Nation policy, American prices are tied to the lowest price paid in countries with comparable living standards, and Italian prices are generally far below US prices, a gap reported to be leading some companies to slow their requests for marketing authorisation in Italy.
Robert Nisticò, director of Aifa, described the agency's approach as follows.
“We are working with all our strength to make this treatment accessible to patients as quickly as possible, within a framework of sustainability.”
Side effects and next steps
The most frequently reported adverse reactions in studies were diarrhoea, skin rashes, inflammation of the mouth lining, nausea and vomiting. The EMA completed its scientific review in just over 100 days under an accelerated procedure, nearly half the 210-day legal timeframe. Member states are carrying out a joint clinical assessment through the Coordination Group for the Assessment of Health Technologies, with its report expected in December 2026. Once national reimbursement is agreed, the drug can be prescribed to adults with metastatic pancreatic ductal adenocarcinoma who have already received therapy.
Ask about this text
Sources and context
- vrtnws.beEuropean Commission approves promising treatment for pancreatic cancerEuropese Commissie keurt veelbelovende behandeling tegen pancreaskanker goed | VRT NWS Nieuws · original in Dutch
- Mediafax.roA new treatment for metastatic pancreatic cancer, authorized by the ECUn nou tratament pentru cancerul pancreatic metastatic, autorizat de CE · original in Romanian
- ANSA.itPancreatic cancer, European Commission ok for drug that increases survivalTumore pancreas, da Commissione europea ok a farmaco che aumenta sopravvivenza - Focus Tumore news · original in Italian
- Notícias ao MinutoEC authorizes new treatment for metastatic pancreatic cancerCE autoriza novo tratamento para cancro do pâncreas metastático · original in Portuguese
- Mark Goldsmith
- Chief executive and chair of Revolution Medicines, the developer of Daraxonrasib
- Places
- United States
- Organizations
- European Union
Pollar is free and carries no ads in the text. Its members keep it going.
Support Pollar